This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
(MedPage Today) -- NEW YORK CITY -- Researchers eked out evidence of a small clinical benefit with the Sentinel cerebral embolic protection (CEP) device in transcatheter aorticvalve replacement (TAVR) -- and pointed to the patients more likely.
Data shows, versus surgery, the Evolut transcatheter aorticvalve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Grubb, M.D.,
TAVR and SAVR are procedures to replace a damaged aorticvalve that is not functioning properly. TAVR and SAVR are procedures to replace a damaged aorticvalve that is not functioning properly. Researchers randomly assigned half of the participants to undergo TAVR and the other half to SAVR.
We know TAVI is in the striking distance , to literally take over most aorticvalve interventions. While the numbers increase, still the debate between SAVR and TAVR is riddled with speculation, skepticism, and absolute confidence. Lastly, TAVI’s lifespan* is currently less than half of a mechanical valve.
Molham Aldeiri , have successfully performed the first series of transcarotid Transcatheter AorticValve Replacement (TAVR) procedures ever done in Southeast Houston. TAVR , whether through the groin approach or neck approach, only requires a half-inch or inch incision.
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aorticvalve replacement (TAVR) System compared to surgical aorticvalve replacement (SAVR) and other TAVRvalves.
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aorticvalve in the heart— transcatheter aorticvalve replacement (TAVR)—and surgical aorticvalve replacement (SAVR).
SAVR after TAVR Surgical aorticvalve replacement after prior TAVR is the fastest-growing cardiac surgery procedure in the U.S. The majority require explant of the TAVR device and SAVR, which significantly increases the risk of operative mortality and stroke. and 3.8%, respectively.
Among patients with asymptomatic severe aortic stenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes.
According to the Centers for Disease Control and Prevention (CDC), heart disease and stroke rank as the first and fifth leading causes of death in the nation. About 276,000 patients have undergone a TAVR procedure in the United States.
What is the relationship between diffusion-weighted magnetic resonance imaging (DW-MRI) total lesion number (TLN), individual lesion volume (ILV), and total lesion volume (TLV) with clinical stroke outcomes after transcatheter aorticvalve replacement (TAVR)?
TAVR was found to bring no increased risks and was associated with substantially decreased rates of death or stroke at one year in low-risk patients, compared with surgical aorticvalve replacement (SAVR), according to results from the DEDICATE-DZHK6 study presented during a Late-Breaking Clinical Trial session at ACC.24
Cardiac Surgery after Transcatheter AorticValve Replacement: Trends and Outcomes The researchers set out to document trends and outcomes in cardiac surgery following transcatheter aorticvalve replacement (TAVR), a topic gaining importance as reports of subsequent cardiac operations and early TAVR explantations increase.
In light of the growing number of patients undergoing transcatheter aorticvalve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 19.0%, p=0.57), as well as stroke at 30 days (2.0%
Objective To evaluate whether transcatheter or surgical aorticvalve replacement (TAVR or SAVR) affects clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aortic stenosis (AS). <aorticvalve area (AVA)<1.5 <aorticvalve area (AVA)<1.5 cm 2 , 3.0<peak
BACKGROUND:Current guidelines recommend surgical aorticvalve replacement (SAVR) for patients with severe aortic stenosis and unfavorable iliofemoral access. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% andP=0.001, respectively).
Seven studies showed that TAVR patients had a similar 1-year stroke risk to SAVR patients (OR 0.92, 95% CI 0.64 In the TIA case, there was no evidence of a significant difference between TAVR and SAVR in the risk of having a transient ischemic attack within 30 days following surgery (OR 0.93, 95% CI 0.24 to 1.17, p=0.30, I2 3%).
In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aorticvalve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
TAVR in heart failure. ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.
The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. percentage points—in one-year bioprosthetic valve dysfunction favoring the Evolut platform. of those receiving the SAPIEN valve.
The EARLY TAVR trial results demonstrate that early transcatheter aorticvalve implantation in patients with asymptomatic severe aortic stenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
Patients with bicuspid aorticvalves (BAV) are predisposed to the development of aortic stenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR) in patients with BAV.
BackgroundAcute ischemic stroke complicates 2% to 3% of transcatheter aorticvalve replacements (TAVRs). The aortic arch morphology was determined via a manual review of the pre‐TAVR computed tomography images. Fifty‐seven patients (1.7%) experienced a periprocedural stroke. versus 1.7%;P=0.01).
BackgroundValveinvalve transcatheter aorticvalve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration.
Objective Postprocedural ischaemic and bleeding risks after transcatheter aorticvalve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.
BackgroundCurrent guidelines and expert consensus recommend lifelong single antiplatelet therapy for patients undergoing transcatheter aorticvalve replacement who have no indication for anticoagulation or dual antiplatelet therapy. Journal of the American Heart Association, Ahead of Print.
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aorticvalve replacement (TAVR) using Evolut TAVR compared to surgical aorticvalve replacement (SAVR) for low-risk patients. At Medtronic, we continue to emphasize that valve design matters.
Introduction:Subclinical leaflet thrombosis is an increasingly recognized complication in patients undergoing transcatheter aorticvalve replacement (TAVR). Patients with hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RELM) have a higher incidence of strokes and transient ischemic attacks.
Abstract: Transcatheter aorticvalve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.
Background: Atrial fibrillation (AF) is common in patients undergoing transcatheter aorticvalve replacement (TAVR) and is associated with increased risk of bleeding and stroke. Patients were randomized 1:1 to TAVR+LAAO or TAVR+medical therapy. For the composite primary endpoint, TAVR+.LAAO
The objectives of this study were to compare the hemodynamic and clinical outcomes between transcatheter aorticvalve replacement (TAVR) and surgical aorticvalve replacement (SAVR) in patients with a SAA.Methods:Prospective multicenter international randomized trial performed in 15 university hospitals.
Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aorticvalve replacement (TAVR) outcomes for aortic stenosis. The CABG SYNTAX score did not influence the prognosis after TAVR.
Among patients at low surgical risk who underwent TAVR or surgery, there was no apparent difference between groups in the incidence of the composite end point of death, stroke, or rehospitalization at 5 years.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Database, Study in Low-Risk Patients Reveals 5-year Survival Rate of 93% October 17, 2023, Chicago, IL – A study published today in The Annals of Thoracic Surgery demonstrates outstanding long-term survival following low-risk isolated surgical aorticvalve replacement (SAVR). The average age of patients was 74.2
SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aorticvalve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve.
Stroke stands as a major contributor to global morbidity and mortality, imposing a substantial burden on patients, societies, and healthcare systems worldwide. Within the realm of transcatheter aorticvalve replacement (TAVR), stroke emerges as a recognized adverse event, manifesting at various stages during and after the procedure.
Stroke, Volume 56, Issue Suppl_1 , Page ATP316-ATP316, February 1, 2025. Background:Despite improvements in the safety of transcatheter aorticvalve replacement (TAVR), ~4% of patients experience a procedure-related stroke. Further research is needed to assess confounding factors as well.
Objective To compare long-term cardiovascular (CV) outcomes between men and women with aortic stenosis (AS) undergoing aorticvalve replacement (AVR) by the type of valve implant. In the TAVR cohort, men suffered a higher risk of death (HR: 1.24; 95% CI: 1.07 to 1.69, p<0.001) was observed in men.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content